WO2001061007A3 - Fibroblast growth factor-23 molecules and uses thereof - Google Patents
Fibroblast growth factor-23 molecules and uses thereof Download PDFInfo
- Publication number
- WO2001061007A3 WO2001061007A3 PCT/US2001/004778 US0104778W WO0161007A3 WO 2001061007 A3 WO2001061007 A3 WO 2001061007A3 US 0104778 W US0104778 W US 0104778W WO 0161007 A3 WO0161007 A3 WO 0161007A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- polypeptides
- fibroblast growth
- fgf
- molecules
- Prior art date
Links
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 title abstract 5
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 239000011230 binding agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01914373A EP1257645A2 (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor-23 molecules and uses thereof |
JP2001560377A JP2005508131A (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor-23 molecule and uses thereof |
CA002398603A CA2398603A1 (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor-23 molecules and uses thereof |
AU39767/01A AU3976701A (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor-23 molecules and uses thereof |
MXPA02007619A MXPA02007619A (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor 23 molecules and uses thereof. |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18244200P | 2000-02-15 | 2000-02-15 | |
US60/182,442 | 2000-02-15 | ||
US19890300P | 2000-04-20 | 2000-04-20 | |
US60/198,903 | 2000-04-20 | ||
US74858101A | 2001-02-15 | 2001-02-15 | |
US09/748,581 | 2001-02-15 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001061007A2 WO2001061007A2 (en) | 2001-08-23 |
WO2001061007A3 true WO2001061007A3 (en) | 2002-03-14 |
WO2001061007A9 WO2001061007A9 (en) | 2002-04-18 |
Family
ID=27391551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/004778 WO2001061007A2 (en) | 2000-02-15 | 2001-02-15 | Fibroblast growth factor-23 molecules and uses thereof |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1257645A2 (en) |
JP (1) | JP2005508131A (en) |
AU (1) | AU3976701A (en) |
CA (1) | CA2398603A1 (en) |
MX (1) | MXPA02007619A (en) |
WO (1) | WO2001061007A2 (en) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003531583A (en) * | 2000-03-08 | 2003-10-28 | カイロン コーポレイション | Human FGF-23 gene and gene expression product |
AU2001245535A1 (en) * | 2000-03-08 | 2001-09-17 | Chiron Corporation | Human fgf-23 gene and gene expression products |
ES2340662T3 (en) | 2000-07-19 | 2010-06-08 | Advanced Research And Technology Institute | FIBROBLAST GROWTH FACTOR (FGF23) NEW PROCEDURE FOR USE. |
EP1310554B1 (en) | 2000-08-11 | 2010-05-26 | Kyowa Hakko Kirin Co., Ltd. | Polypeptides controlling phosphoric acid metabolism, calcium metabolism, calcification and vitamin d metabolism and dnas encoding the same |
WO2002088358A2 (en) * | 2001-04-26 | 2002-11-07 | Geneprot, Inc. | Human fibroblast growth factor-related compositions |
AU2003202472B2 (en) * | 2001-12-28 | 2009-11-26 | Kyowa Kirin Co., Ltd. | Antibodies against fibroblast growth factor 23 |
US7094551B2 (en) | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
US7883705B2 (en) | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
MX342553B (en) * | 2008-04-29 | 2016-10-04 | Novartis Ag | Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods. |
JP6254524B2 (en) | 2011-07-01 | 2017-12-27 | エヌジーエム バイオファーマシューティカルス,インコーポレーテッド | Compositions, uses and methods for the treatment of metabolic disorders and diseases |
AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
AU2013370404B2 (en) | 2012-12-27 | 2017-11-02 | Ngm Biopharmaceuticals, Inc. | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
HRP20200881T1 (en) | 2014-01-24 | 2020-09-04 | Ngm Biopharmaceuticals, Inc. | BETA-KLOTHO DOMAIN 2 BINDING ANTIBODIES AND PROCEDURES FOR THEIR USE |
US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RU2729161C2 (en) | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Pharmaceutical compositions containing peptide versions, and methods of using them |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
JP2017537926A (en) | 2014-12-04 | 2017-12-21 | ノバルティス アーゲー | Methods and compositions using KLOTHO variant polypeptides |
WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
CA3003616C (en) | 2015-11-09 | 2020-07-28 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027100A1 (en) * | 1997-11-25 | 1999-06-03 | Genentech, Inc. | Fibroblast growth factor-19 |
WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
WO2000073454A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001049740A1 (en) * | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Novel fgf homolog zfgf12 |
-
2001
- 2001-02-15 EP EP01914373A patent/EP1257645A2/en not_active Withdrawn
- 2001-02-15 AU AU39767/01A patent/AU3976701A/en not_active Abandoned
- 2001-02-15 CA CA002398603A patent/CA2398603A1/en not_active Abandoned
- 2001-02-15 MX MXPA02007619A patent/MXPA02007619A/en unknown
- 2001-02-15 WO PCT/US2001/004778 patent/WO2001061007A2/en active Search and Examination
- 2001-02-15 JP JP2001560377A patent/JP2005508131A/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999027100A1 (en) * | 1997-11-25 | 1999-06-03 | Genentech, Inc. | Fibroblast growth factor-19 |
WO2000060085A1 (en) * | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
WO2000073454A1 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001049740A1 (en) * | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Novel fgf homolog zfgf12 |
Non-Patent Citations (2)
Title |
---|
DATABASE EMHUM EMBL Heidelberg, Germany; 12 July 1999 (1999-07-12), MUZNY D ET AL.: "Homo sapiens 12p13 BAC RPCI11-388F6", XP002177850 * |
See also references of EP1257645A2 * |
Also Published As
Publication number | Publication date |
---|---|
EP1257645A2 (en) | 2002-11-20 |
CA2398603A1 (en) | 2001-08-23 |
MXPA02007619A (en) | 2002-12-13 |
JP2005508131A (en) | 2005-03-31 |
AU3976701A (en) | 2001-08-27 |
WO2001061007A2 (en) | 2001-08-23 |
WO2001061007A9 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001061007A3 (en) | Fibroblast growth factor-23 molecules and uses thereof | |
WO2001070977A3 (en) | Fibroblast growth factor receptor-like molecules and uses thereof | |
WO2002002624A3 (en) | B7-like molecules and uses thereof | |
WO2002024891A3 (en) | B7-like molecules and uses thereof | |
WO2001072957A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
WO2001068854A3 (en) | Fibroblast growth factor-like molecules and uses thereof | |
WO2002008285A3 (en) | Il-17 molecules and uses thereof | |
WO2001092308A3 (en) | Cystine-knot polypeptides: cloaked-2 molecules and uses thereof | |
WO2002000724A3 (en) | Thymic stromal lymphopoietin receptor molecules and uses thereof | |
WO2001079444A3 (en) | Albumin fusion proteins | |
WO2003060071A3 (en) | Albumin fusion proteins | |
WO2002020762A3 (en) | Tnf receptor-like molecules and uses thereof | |
WO2001068859A3 (en) | Il-17 receptor like molecules and uses thereof | |
WO2001068705A3 (en) | Il-17 receptor like molecules and uses thereof | |
WO2003024991A3 (en) | Tall-1 receptor molecules and uses thereof | |
WO2001042474A3 (en) | Interferon-like molecules and uses thereof | |
WO2003087338A3 (en) | Her-2 receptor tyrosine kinase molecules and uses thereof | |
WO2002000723A3 (en) | Thymic stromal lymphopoietin receptor molecules and uses thereof | |
WO2002010388A3 (en) | C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF | |
WO2002097046A3 (en) | B7 related protein-2 molecules and uses thereof | |
WO2003055980A3 (en) | Il-17 like molecules and uses thereof | |
WO2001059120A3 (en) | Il-17 like molecules and uses thereof | |
WO2001074903A3 (en) | Cd20/ige-receptor like molecules and uses thereof | |
WO2002083736A3 (en) | G-protein coupled receptor molecules and uses thereof | |
WO2002044379A3 (en) | Transforming growth factor-beta-related molecules and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/13-13/13; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39767/01 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2398603 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/007619 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 560377 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001914373 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001914373 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001914373 Country of ref document: EP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |